HUT73693A - Oxygen-reduced aqueous solution of factor viii - Google Patents

Oxygen-reduced aqueous solution of factor viii

Info

Publication number
HUT73693A
HUT73693A HU9503171A HU9503171A HUT73693A HU T73693 A HUT73693 A HU T73693A HU 9503171 A HU9503171 A HU 9503171A HU 9503171 A HU9503171 A HU 9503171A HU T73693 A HUT73693 A HU T73693A
Authority
HU
Hungary
Prior art keywords
factor viii
aqueous solution
pct
oxygen
present
Prior art date
Application number
HU9503171A
Other languages
English (en)
Other versions
HU215263B (hu
HU9503171D0 (en
Inventor
Angelica Fatouros
Thomas Oesterberg
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of HU9503171D0 publication Critical patent/HU9503171D0/hu
Publication of HUT73693A publication Critical patent/HUT73693A/hu
Publication of HU215263B publication Critical patent/HU215263B/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
HU9503171A 1993-05-07 1994-03-24 VIII faktor csökkentett oxigéntartalmú vizes oldata HU215263B (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939301581A SE9301581D0 (sv) 1993-05-07 1993-05-07 Protein formulation

Publications (3)

Publication Number Publication Date
HU9503171D0 HU9503171D0 (en) 1996-01-29
HUT73693A true HUT73693A (en) 1996-09-30
HU215263B HU215263B (hu) 1998-11-30

Family

ID=20389868

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9503171A HU215263B (hu) 1993-05-07 1994-03-24 VIII faktor csökkentett oxigéntartalmú vizes oldata

Country Status (24)

Country Link
US (1) US5962650A (hu)
EP (1) EP0700299B1 (hu)
JP (1) JP3751633B2 (hu)
KR (1) KR100304143B1 (hu)
CN (1) CN1113655C (hu)
AT (1) ATE218354T1 (hu)
AU (1) AU681883B2 (hu)
CA (1) CA2161350C (hu)
CZ (1) CZ293527B6 (hu)
DE (1) DE69430745T2 (hu)
DK (1) DK0700299T3 (hu)
EE (1) EE03118B1 (hu)
ES (1) ES2177579T3 (hu)
FI (1) FI111910B (hu)
HU (1) HU215263B (hu)
NO (1) NO321769B1 (hu)
NZ (1) NZ266031A (hu)
PL (1) PL174866B1 (hu)
PT (1) PT700299E (hu)
RU (1) RU2142290C1 (hu)
SE (1) SE9301581D0 (hu)
SK (1) SK283002B6 (hu)
WO (1) WO1994026286A1 (hu)
ZA (1) ZA942251B (hu)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US5929031A (en) * 1995-05-02 1999-07-27 Baxter Biotech Technology Sarl Storage stable hemoglobin solutions
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
PT2130554E (pt) * 1999-02-22 2012-11-19 Univ Connecticut Formulações de factor viii isentas de albumina
ATE310533T1 (de) * 1999-07-13 2005-12-15 Zusammensetzungen mit stabilem faktor viii
JP3466516B2 (ja) * 1999-09-07 2003-11-10 科学技術振興事業団 安定保存可能な酸素輸液剤
WO2003055511A1 (en) * 2001-12-21 2003-07-10 Novo Nordisk A/S Liquid composition of modified factor vii polypeptides
RU2357751C2 (ru) * 2001-12-21 2009-06-10 Ново Нордиск Хелт Кэр Аг Жидкая композиция полипептидов фактора vii
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
EP2283856B1 (en) 2002-06-21 2017-09-20 Novo Nordisk Health Care AG Stabilised solid compositions of factor VIIa polypeptides
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
DE602004025100D1 (de) 2003-05-23 2010-03-04 Novo Nordisk Healthcare Ag Stabilisierung von proteinen in lösung
ES2382157T3 (es) 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
JP5306597B2 (ja) * 2003-07-01 2013-10-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体水性薬学的組成物
ES2574581T3 (es) 2003-08-14 2016-06-20 Novo Nordisk Health Care Ag Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
AU2004298789A1 (en) 2003-12-19 2005-06-30 Novo Nordisk Health Care Ag Stabilised compositions of factor VII polypeptides
ES2449044T3 (es) * 2004-05-03 2014-03-18 Emory University Procedimiento de administración de fVIII sin dominio B porcino
US7504377B2 (en) 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin
US7494974B2 (en) 2006-10-24 2009-02-24 Ikor, Inc. Carboxymethylated cross-linked tetrameric hemoglobin
PT1982731E (pt) * 2007-04-17 2010-07-06 Schwabe Willmar Gmbh & Co PROCESSO PARA PRODUÆO DE SOLUÎES DE EXTRACTOS DE PELARGËNIO ESTáVEIS EM ARMAZENAMENTO
JP5323072B2 (ja) * 2007-07-11 2013-10-23 ノボ・ノルデイスク・エー／エス 混合方式又は多様式樹脂を使用する第ｖｉｉｉ因子の精製
EP2113564A1 (en) 2008-05-01 2009-11-04 Arecor Limited Protein formulation
AU2009284113B2 (en) 2008-08-21 2015-05-14 Octapharma Ag Recombinantly produced human factor VIII and IX
AU2009289212B2 (en) * 2008-09-03 2015-02-12 Octapharma Ag New protecting compositions for recombinantly produced factor VIII
US20100168018A1 (en) 2008-11-07 2010-07-01 Baxter International Inc. Factor viii formulations
AU2010258752B2 (en) * 2009-06-09 2015-07-09 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
GB0915480D0 (en) * 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
US11284616B2 (en) 2010-05-05 2022-03-29 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US9199016B2 (en) 2009-10-12 2015-12-01 New Health Sciences, Inc. System for extended storage of red blood cells and methods of use
ES2959120T3 (es) 2010-08-25 2024-02-20 Hemanext Inc Método para potenciar la calidad y la supervivencia de glóbulos rojos durante el almacenamiento
SG190136A1 (en) 2010-11-05 2013-07-31 Baxter Int A new variant of antihemophilic factor viii having increased specific activity
EP4218412A1 (en) 2010-11-05 2023-08-02 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US9067004B2 (en) 2011-03-28 2015-06-30 New Health Sciences, Inc. Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly
PT3061509T (pt) 2011-08-10 2019-09-10 New Health Sciences Inc Depleção de leucócito, oxigénio e/ou co2 integrada e dispositivo de filtro de separação de plasma
ES2900298T3 (es) 2013-02-28 2022-03-16 Hemanext Inc Dispositivo de agotamiento de gas para productos sanguíneos
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
CA2978940C (en) 2015-03-10 2023-10-17 New Health Sciences, Inc. Oxygen reduction disposable kits, devices and methods of use thereof
KR102661405B1 (ko) 2015-04-23 2024-04-25 헤마넥스트 인코포레이티드 혐기성 혈액 저장 용기
BR122021024410B1 (pt) 2015-05-18 2022-05-03 Hemanext Inc Métodos para gerenciar um banco de sangue e para prover fornecimento de produtos de sangue total armazenados para medicina de transfusão
KR20190017747A (ko) 2016-05-27 2019-02-20 뉴 헬스 사이언시즈 인코포레이티드 혐기성 혈액 저장 및 병원체 불활성화 방법
WO2020030572A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2896381A (en) * 1954-05-27 1959-07-28 Hodes Lange Corp Method and apparatus for treating and filling ampoules
US3143471A (en) * 1962-01-18 1964-08-04 Merck & Co Inc Argon method of drying and preserving lyophilized therapeutic products
US4165370A (en) * 1976-05-21 1979-08-21 Coval M L Injectable gamma globulin
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3144705C2 (de) * 1981-11-11 1983-12-08 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung eines lagerstabilen, vernetzten Hämoglobinpräparates mit hoher Sauerstoff-Transportkapazität, sowie das nach diesem Verfahren hergestellte Hämoglobinpräparat
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4727027A (en) * 1983-05-02 1988-02-23 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
EP0212040B1 (de) * 1985-08-05 1990-05-23 IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte Verfahren zur Herstellung von Präparationen auf Basis von Blutgerinnungsfaktoren
US4709819A (en) * 1986-07-23 1987-12-01 Environmental Diagnostics, Inc. Method for preserving plated media and product
CA1292686C (en) * 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
GB8808810D0 (en) * 1988-04-14 1988-05-18 Biopharm Clinical Research Ltd Heparin-containing formulations
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
WO1996013319A1 (en) * 1994-10-31 1996-05-09 Kimberly-Clark Worldwide, Inc. High density nonwoven filter media

Also Published As

Publication number Publication date
NO954457D0 (no) 1995-11-07
PL174866B1 (pl) 1998-09-30
JP3751633B2 (ja) 2006-03-01
NO954457L (no) 1995-11-07
CZ286995A3 (en) 1996-05-15
EP0700299B1 (en) 2002-06-05
JPH08509745A (ja) 1996-10-15
CN1122573A (zh) 1996-05-15
SK138395A3 (en) 1997-02-05
HU215263B (hu) 1998-11-30
KR960702317A (ko) 1996-04-27
CA2161350A1 (en) 1994-11-24
CZ293527B6 (cs) 2004-05-12
CA2161350C (en) 2007-10-30
FI955305A (fi) 1995-11-06
AU6659794A (en) 1994-12-12
NZ266031A (en) 1997-04-24
NO321769B1 (no) 2006-07-03
US5962650A (en) 1999-10-05
FI955305A0 (fi) 1995-11-06
EP0700299A1 (en) 1996-03-13
ATE218354T1 (de) 2002-06-15
RU2142290C1 (ru) 1999-12-10
KR100304143B1 (ko) 2001-11-22
SE9301581D0 (sv) 1993-05-07
ZA942251B (en) 1994-11-01
DE69430745T2 (de) 2002-10-17
DE69430745D1 (de) 2002-07-11
PL311567A1 (en) 1996-02-19
HU9503171D0 (en) 1996-01-29
WO1994026286A1 (en) 1994-11-24
EE03118B1 (et) 1998-10-15
AU681883B2 (en) 1997-09-11
SK283002B6 (sk) 2003-01-09
FI111910B (fi) 2003-10-15
ES2177579T3 (es) 2002-12-16
PT700299E (pt) 2002-11-29
DK0700299T3 (da) 2002-09-23
CN1113655C (zh) 2003-07-09

Similar Documents

Publication Publication Date Title
HU9503171D0 (en) Oxygen-reduced aqueous solution of factor viii
BR9607922A (pt) Produto medicamentoso final de uma proteína de plasma processos para preparar o produto medicamentoso final para melhorar a estabilidade de longo prazo de uma proteína de plasma e para tratar hemofilia e uso de um produto medicamentoso final
Pfister et al. Ascorbic acid in the treatment of alkali burns of the eye
ATE73671T1 (de) Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin.
DE69217045D1 (de) Verfahren zur herstellung von nahrungsmitteln und getränken
EP0804613A4 (en) TUMOR SUPPRESSORGENES, PROTEINS CODED BY THEM AND THE USE OF SUCH GENES AND PROTEINS
PL320342A1 (en) Thrombin inhibitor containing infusion solution, stable during storage
CA2067371A1 (en) Stable hemoglobin based composition and method to store same
SE9402119D0 (sv) Solution
ATE66147T1 (de) Verwendung von pteridinen und/oder purinen oder eines xanthinoxidase-hemmers zur herstellung eines arzneimittels zur behandlung von genetisch bedingten degenerativen netzhauterkrankungen.
GR3022435T3 (en) Destruction of gram negative bacteria
ZA9514B (en) Methods for preventing degradation of protein c

Legal Events

Date Code Title Description
HPC4 Succession in title of patentee

Owner name: BIOVITRUM AB, SE

MM4A Lapse of definitive patent protection due to non-payment of fees